
| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-27 | 2026-03-02 | Flynn James E | Director | Purchase | 5.00M | $5.00 | $25.00M | 10.62M | View ↗ | |
| 2026-02-27 | 2026-03-02 | Hamilton Thomas Edward | Director | Purchase | 100.0K | $5.00 | $500K | 664.8K | View ↗ | |
| 2026-02-27 | 2026-03-02 | THOMAS FRANK E | Director | Purchase | 5,000 | $5.00 | $25K | 7,000 | View ↗ |
No annual data found.
Exploring US High Growth Tech Stocks This May 2026
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia
Wedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13